We have attached herewith earning call transcript. Kindly take the same on your record. Thank you.

AI summary - Q1 FY27 consolidated revenue 87.62 Cr (+163% y-y), EBITDA 15.65 Cr, PAT 8.28 Cr - EBITDA margin moderated to ~17% due to raw material price surge and consolidation of Remember India Health Links - Expect EBITDA margin normalization to 25-30% range by Q2/Q3 FY27 as raw material prices stabilize - FY27 revenue guidance raised to 350-400 Cr, driven by organic growth and acquisitions - Capacity expanded to 1400-1600 MT; utilization ~65-70%; new 1200 MT capacity commissioning expected Q1 FY28 - Mid-term target: ~30% revenue CAGR over next 3 years with integrated pharma platform - Consolidated EBITDA margin expected 25-27% for FY27; PAT margin guidance 12-13% - Working capital days ~170-180; positive operating cash flow expected by FY27 end